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Extraskeletal myxoid chondrosarcoma (EMC) is a rare soft-tissue sarcoma, which primarily occurs deep in the
extremities, especially in skeletal muscle, or tendon. EMC of the pleura has been described, however, no case of
primary EMC arising from lung has been previously reported. We describe herein, a 51-year-old Asian female initially
manifested with signs of severe anemia who presented with a lung mass unrelated to pleura that was
morphologically typical EMC, with strong immunoreactivity for vimentin and NSE. Two weeks after resection, the
anemia was cured. The patient continued with follow-up, without sign of abnormality 32 months after operation.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
2882199847396682
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Extraskeletal myxoid chondrosarcoma (EMC) was first
reported by Enzinger and Shiraki in 1972 as a rare
soft-tissue sarcoma, which primarily occurs deep in the
extremities, especially in skeletal muscle, or tendon [1].
Unusual locations include tongue, retroperitoneum,
spine, intracranium, testis, inguinal region, synovium,
mammary gland, and labium.
We report the clinicopathological features of a female
patient with EMC of the lung initially manifested with
asymptomatic lung mass with severe anemia determined
by the evidence of histological and immunohistochem-
ical examination.Case presentation
A 51-year-old Asian woman, who was a social worker,
nonsmoker, was admitted to the Department of
Hematology in August 2009 because of severe anemia
and emaciation without cough, sputum, and hemoptysis.
Physical examination revealed marked sign of anemia* Correspondence: qianjunz@buffalo.edu
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reproduction in any medium, provided the orbut failed to find any masses in the soft tissue of extrem-
ities or pelvis through palpation. A computed tomog-
raphy (CT) scan disclosed a 41 × 33 mm parenchymal
mass on apico-posterior segment of left upper lobe, CT
value was 26 Hounsfield unit (HU). The patient had a
10-year history of left lung nodule by chest x-ray, how-
ever, no films were available currently. Whole blood cell
count was characterized as microcytic hypochromic
anemia, with RBC 2.67 × 1012/L, Hb 54 g/L. Serum iron
was 2.2 μmol/L, total iron binding capacity 74 μmol/L.
Serum IgG 18.3 g/L, and a serum protein electrophoresis
examination found no monoclonal protein. Tumor mar-
kers such as carcinoembryonic antigen (CEA) and
neuron specific enolase (NSE) were all negative. Bone
marrow smear and biopsy showed normocellularity with
lower intracellular iron. Bronchoscopic examination with
biopsy, brushing and washing found no abnormality. A
bone scan was negative for other lesions. There were no
metastatic signs in brain and abdomen by CT scan. After
the therapy of iron supplement and red blood cell trans-
fusion, Hb was slightly elevated. The patient was trans-
ferred for surgery on October, and thoracic CT scan
showed the tumor was 55 × 48 mm, with CT value 34
HU, 54 HU in contrast enhancement scanning (Figure 1).
After anemia had been cured by transfusion, left ex-
ploratory thoracotomy was planned. Operation revealedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Preoperative radiological features: large mass
involving the left upper lobe.
Figure 2 Low magnification shows the well-circumscribed
tumor with multinodular architecture. ×40.
Figure 3 High power image of spindle cells in cords present
within a myxoid background. The cells are vaculoated showing
nuclear atypia ×400.
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http://www.diagnosticpathology.org/content/7/1/112a peripheral pulmonary mass on left upper lobe without
pleural indentation or swollen lymph node in hilum and
mediastinum, and the patient underwent left upper lob-
ectomy with systemic lymph node dissection. The pa-
tient recovered smoothly and was discharged in a good
condition without anemia after two weeks. Follow-up
continued every three month after operation by chest
CT scan and CBC. There was no sign of abnormality
32 months after operation.
Grossly, the left upper lobe measured 20 cm×10.5 cm×
4 cm, and the lesion was located in lung parenchyma 2
cm away from the resection margin of left upper bron-
chus. On cut surface, the tumor measured 5 cm×5 cm×
3.2 cm in size, pale gray, soft, well demarcated, lobulated
with a gelatinous texture.
Microscopic examination showed the characteristic
features of EMC, including a well-circumscribed, multi-
lobulated architecture separated by incomplete fibrous
septae, relatively uniform oval to short spindle shaped
cells arranged in short anastomosing strands and cords
embedded in abundant myxoid matrix (Figure 2). The
cells were characterized by hyperchromatic nucleus and
tiny nucleolus, some of which showed grooves (Figure 3).
There were a large number of plasma cells and a few
lymphocytes in fibrous septae to form the compact zone
(Figure 4). No hyaline cartilage was seen. Mitotic figures
were 1/50HPF. No infiltration into adjacent lung tissue
was seen.
Special stains revealed glycogen in the cytoplasm of
the tumor cells, while the surrounding extracellularmatrix was positive with Alcian blue stain. By immuno-
histochemical study, vimentin and NSE were strongly
expressed in the tumor cells (Figure 5, 6), while S-100
protein was weak and focal (Figure 7). The other mar-
kers including cytokeratin, epithelial membrane antigen
(EMA), P63, smooth muscle actin (SMA), muscle spe-
cific actin (MSA), desmin, KP1, calretinin were all nega-
tive. IFN-β was immunopositive in the tumor cells.
Discussion
EMC has mainly been reported in the areas of orthope-
dics, neurosurgery, and otolaryngology [1]. As with our
case, the characteristic features of well-circumscribed,
multilobulated configuration with incomplete fibrous
septae, oval to spindle shaped cells arranged in short
Figure 4 Medium power image illustrates the plasma cells and
lymphocytes surrounding the tumor.
Figure 6 The tumors are strongly immunopositve to neuron-
specific enolase.
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http://www.diagnosticpathology.org/content/7/1/112anastomosing strands embedded in abundant myxoid
matrix and typical histochemical findings favored the
diagnosis of EMC [2]. Since the lesion located at the per-
iphery of the lung, fine needle aspiration biopsy (FNAB)
should be initially done to help diagnosis. Although
cytologic characteristics are not decisive for diagnosis,
the presence of intranuclear cytoplasmic inclusions,
grooves and cytoplasmic vacuolization could be suggest-
ive to EMC diagnosis [3]. S-100 protein was initially
found in most EMC, but recent studies proved that less
than 20 % of EMC are S-100 positive [4]. In some cases
of EMC, there is neuroendocrine differentiation [5]. A
specific chromosomal translocation t(9;22)(q22;q12)
leading to a fusion gene, EWS-CHN has been found in
75 % EMC cases [6], and another fusion gene TAF2N-
CHN caused by t(9;17)(q22;q11.2) translocation hasFigure 5 Photomicrographs shows the strong expression of
Vimentin in tumor cells.recently been identified [5]. Although primaries should
not have difficulty in diagnosis for experienced patholo-
gists, the morphologic differential diagnosis in our case
are parachordoma, chordoma, soft tissue chondroma,
extraskeletal mesenchymal chondrosarcoma,as well as
pulmonary metastases of EMC. Parachordoma is an in-
dolent soft tissue tumor predominantly in the extrem-
ities and trunk, occasionally in the chest wall. The
diagnosis is excluded because there were no typical his-
topathologic and immunohistochemical features of para-
chordoma such as plasma cell-like appearance of the
tumor cells with chondrometaplasia myoepithelium, and
expression of cytokeratin, and EMA. Chordoma appears
as lobulated tumors, with cord pattern tumor cells scat-
tering within abundant myxoid stroma. The diagnosis is
ruled out by a lack of physaliferous cells, and noFigure 7 S-100 protein expression was weak and focal in the
tumor.
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http://www.diagnosticpathology.org/content/7/1/112expression of cytokeratin. Soft tissue chondroma com-
posed of small cells with hyaline cartilage lobule which
lies near the joints of extremities, and S-100 is uniquely
positive. Extraskeletal mesenchymal chondrosarcoma
arising in lung [7], chest wall, pleural and mediastinum
has been reported. The lack of small undifferentiated
cells surrounding narrow vascular spaces in a haeman-
giopericytoid (haemangiopericytoma-like) pattern with
mature cartilage island would exclude extraskeletal mes-
enchymal chondrosarcoma. As lung is the most frequent
site of metastases in EMC, it is necessary to differetiate
primary EMC in lung from lung metastases of EMC.
However, it was not difficult to exclude lung metastases
of EMC originated in the other parts of the body after
comprehensive clinical evaluation and CT scan, with
particular attention to the distal parts of the extremities.
There was not any evidence of tumor in the body other
than in the lung of the patient. Extraosseous (extrame-
dullary) plasmacytoma (EMP) is defined as localized
plasma cell neoplasms arising in tissues other than bone,
and EMP in lung has been reported [8]. In our case,
there are abundant plasma cells and aggregated lympho-
cytes in tumor fibrous septae and adjacent lung tissue
which might be the anti-tumor reaction of immune
system. As to EMP, the neoplastic cells are similar to
normal plasma cells with very few lymphocytes. Last,
our case should also be differentiated from primary
pulmonary sarcomas. Pulmonary myxoid liposarcoma is
multinodular-architecture in myxoid stroma with
Vimentin and S-100 positive which is similar to EMC,
however, lack of lipoblasts and plexiform capillary net-
work exclude the diagnosis [9]. Immunostains can be
helpful to rule out rhabdomyosarcoma, leiomyosar-
coma. Primary and metastatic chondrosarcoma of lung
have been documented, and the multilobular neoplasm
with chondroid and myxoid matrix which is positive to
Vimentin and S-100, negative for epithelial markers
might cause the confusion with EMC [10]. In this case,
absence of predominant chondromatous lesion helps to
exclude chondrosarcoma. Pulmonary carcinosarcoma is
ruled out for lack of carcinomatous component [11].
Although EMC is most common in the soft tissues of
the extremities, in fact, the primary site can be anywhere
in the body [1]. To our knowledge, no case of EMC aris-
ing in lung has been reported to date. Primary EMC of
the pleura has been described by Goetz et al. [12]. From
the CT scan, a parenchymal mass of left upper lobe can
be found with distinct margin from the intact visceral
pleura, which were also proved by microscopic examin-
ation on cut section of tumor. We suggest that the ori-
gin might be primitive mesenchymal cell, or associated
with the tracheobronchial cartilage [13,14].
Anemia is one of the characteristics in this patient
which has not been reported previously in EMCs.Patients afflicted with malignancy often develop anemia,
and some cytokines, particularly TNF-α,TGF-β,IFN-β,
IL-1,are found increasing in many malignant diseases
[15,16]. The function of these cytokines is related to re-
tention of iron in the reticuloendothelial system, gastro-
intestinal tract and liver and exert inhibitory effects on
erythroid precursors [17]. As in our case, expression of
IFN-β in tumor cells, significant in excessive type IFN
signaling, inhibits erythropoiesis through decreased Bcl-
XL expression level and enhanced apoptosis of erythro-
blasts [18]. Also, negative bone marrow cytology rules
out occurrence of primary hematological malignancies,
such as multiple myeloma. It is intriguing that the
anemia was corrected just after the removal of the
tumor, suggesting that the cause of anemia relies on the
tumor itself.
EMC shows a tendency to affect patients beyond their
fifth decade [19]. EMC was initially viewed as a low-
grade sarcoma with prolonged and indolent clinical
course, but recent studies found its unfavorable progno-
sis with high rate of recurrence and metastases [20]. Sig-
nificant in the past history was that our 51-year-old
patient had a left lung nodule examined by routine chest
x-ray check for around 10 years, which was in accord-
ance with those previous reports. Since EMC has a high
rate of recurrence and metastases, and the death caused
by tumor often occurs in a long postoperative period,
sometimes more than 10 years after diagnosis, so we
suggest that frequent and long-term follow up is needed
for our patient.
Conclusion
Our case is the first case of EMC located in the lung. It
highlights the possibility and difficulty of diagnosis of
this rare tumor in the lung, especially in the patients
with history of long-term and slowly-growing lung nodule.
Characteristic histological features supported by immuno-
histochemical reactivities, help to diagnose EMC of the
lung, although it is exceedingly rare in this location.
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